Home › Funds › Paradigm Biocapital Advisors LP › MBX

Paradigm Biocapital Advisors LP position in MBX

MBX BIOSCIENCES INC · Health Care

Paradigm Biocapital Advisors LP reported holding 3,772,885 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$221.2M, representing 4.40% of its reported portfolio and ranking #7 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)3.77M sh
Reported value held$221.17M
Portfolio Weight4.40%
First reportedQ2 2026
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's MBX position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in MBX in Q2 2026 at 2,508,015 shares (US$138.4M). The position peaked in Q3 2026 at 3,772,885 shares, worth US$221.2M. Across 2 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,772,885 shares valued at US$221.2M — an increase of 1,264,870 shares quarter over quarter.. Notable position changes include a 50% increase in Q3 2026 (shares fell 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 2.51M $138.44M New
Q3 2026 3.77M $221.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MBX and 13F data

MBX (MBX BIOSCIENCES INC) is a Health Care company. 61 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MBX

All MBX fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held MBX?

Paradigm Biocapital Advisors LP has disclosed MBX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Paradigm Biocapital Advisors LP's current position in MBX?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 3.77M shares of MBX (MBX BIOSCIENCES INC), valued at $221.17M, representing 4.40% of its reported portfolio and ranking #7.

Has Paradigm Biocapital Advisors LP been buying or selling MBX?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in MBX. The position peaked in Q3 2026 at 3.77M shares.

Which other funds hold MBX?

Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.